← 返回

骨髓瘤的支持治疗——仅治疗克隆是不够的

英文原题:Supportive care in myeloma-when treating the clone alone is not enough.

查看英文原题

Supportive care in myeloma-when treating the clone alone is not enough.

PubMed 2024/12/06(内容时间) Hematology Am Soc Hematol Educ Program Q1 · IF 3.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

近几十年来,多发性骨髓瘤患者总生存期延长。随着CAR-T 细胞疗法和T细胞衔接型双特异性抗体等T细胞重定向疗法出现,预计这一趋势还将继续。但尽管治疗有所改善,治疗相关不良事件仍会损害患者生活质量,凸显优化支持治疗策略、最大程度改善治疗结局的必要性。支持治疗不仅关系患者福祉,也影响治疗依从性,进而可能转化为长期疾病控制。本文介绍:(a)骨病预防;(b)风险适配的血栓预防策略;(c)管理靶向G蛋白偶联受体C类5组D型的T细胞重定向疗法所致靶向肿瘤外毒性;(d)感染预防,重点讨论T细胞重定向治疗期间的感染。

展开英文摘要原文

The overall survival in patients with multiple myeloma has increased over recent decades. This trend is anticipated to further advance with the emergence of T-cell-redirecting therapies, including chimeric antigen receptor T-cell (CAR T) therapy and T-cell-engaging bispecific antibodies.

Despite these therapeutic improvements, treatment-related adverse events impede quality of life. This underscores the imperative of optimizing supportive care strategies to maximize treatment outcomes. Such optimization is crucial not only for patient well-being but also for treatment adherence, which may translate into long-term disease control.

We here describe a) how to prevent bone disease, b) a risk-adapted thrombosis prophylaxis approach, c) the management of on-target, off-tumor toxicity of G-protein-coupled receptor class C group 5 member D-targeting T-cell-redirecting therapies, and d) infectious prophylaxis, with a focus on infections during T-cell-redirecting therapies.

论文信息

作者
Zweegman S、van de Donk NWCJ
单位
Department of Hematology, Amsterdam University Medical Center, Universiteit van Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.Netherlands
文献类型
综述 · 病例报告
期刊
Hematology. American Society of Hematology. Education Program2024 Dec 6
原文标识
PubMed 39643986 · DOI 10.1182/hematology.2024000579